홈 > 시장보고서 > 의약품

시장보고서

상품코드

1800794

맥락막 신생혈관 시장 보고서 : 제품 유형, 진단 종류, 치료 종류, 용도, 지역별(2025-2033년)

Choroidal Neovascularization Market Report by Product Type, Diagnosis (Fluorescein Angiography, Indocyanine Green Angiography, Spectral Domain Optical Coherence Tomography, and Others), Treatment Type, Application, and Region 2025-2033

발행일: 2025년 08월 | 리서치사:

IMARC | 페이지 정보: 영문 124 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 맥락막 신생혈관 시장 규모는 2024년 69억 달러에 달했습니다. 향후 IMARC Group은 시장이 2033년까지 122억 달러에 달해 2025년부터 2033년까지 6.13%의 연평균 성장률(CAGR)을 기록할 것으로 예측했습니다.

맥락막 신생혈관(CNV)은 눈의 맥락막층에 생긴 신생혈관으로, Bruch's membrane과 망막색소상피(RPE)에 영향을 미치는 신생혈관을 말합니다. 그 증상으로는 지질 삼출, 망막하 혈액이나 액체, 중심시야의 왜곡, 부풀어 오름, 흑점 등이 있습니다. 현재 CNV의 진단에는 플루오레세인 혈관조영술(FA), 인도시아닌그린(ICG) 혈관조영술, 광간섭단층촬영(OCT) 스캔 등의 검사가 병용되고 있습니다. 그 결과에 따라 의사는 항혈관내피성장인자(VEGF) 약물, 열 레이저 치료, 광역학 치료(PDT)를 처방하여 혈관의 성장을 막습니다.

노화성 황반변성(ARMD), 안구 히스토플라즈마증, 병적 근시, 혈관근육, 맥락막 파열, 맥락막 및 망막의 염증성 질환의 유병률 증가로 인해 시장이 성장하고 있습니다. 또한, 심각한 건강 상태에 빠지기 쉬운 노령 인구의 증가는 시장 성장을 촉진하는 중요한 요인으로 작용하고 있습니다. 또한, 장기 지속형 항VEGF 약물의 도입과 함께 병용요법의 도입이 증가하면서 CNV 치료에 대한 전 세계 수요를 견인하고 있습니다. 헬스케어 인프라 개선, 연구개발(R&D) 활동 투자 증가 등 다른 요인들도 시장 성장에 기여하고 있습니다.

본 보고서에서 다루는 주요 질문

세계 맥락막 신생혈관 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 성장할 것인가?
COVID-19가 세계 맥락막 신생혈관 시장에 미치는 영향은?
주요 지역 시장이란?
제품 유형별 시장 분석은?
진단 유형별 시장 현황은?
치료 유형별 시장 분석은?
용도별 시장 내역은?
산업 가치사슬의 다양한 단계는 무엇인가?
업계의 주요 촉진요인과 과제는 무엇인가?
세계 맥락막 신생혈관 시장의 구조와 주요 기업은?
업계 내 경쟁은 어느 정도인가?

시장 구조
주요 기업
주요 기업 개요
- Bausch Health Companies Inc.
- Bayer AG
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche AG
- MaaT Pharma
- Novartis AG
- Pfizer Inc.
- Quark Pharmaceuticals Inc.(SBI ALApharma Co., Limited)
- Regeneron Pharmaceuticals Inc.
- Sanwa Kagaku Kenkyusho Co. Ltd.(SUZUKEN CO., LTD.)

KSM 25.09.04

The global choroidal neovascularization market size reached USD 6.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.13% during 2025-2033.

Choroidal neovascularization (CNV) refers to the creation of new blood vessels in the choroid layer of the eyes affecting the Bruch's membrane and retinal pigment epithelium (RPE). Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision. At present, a combination of procedures, such as fluorescein angiography (FA), indocyanine green (ICG) angiography and optical coherence tomography (OCT) scanning, are utilized for diagnosing CNV. As per the results, doctors then prescribe anti-vascular endothelial growth factor (VEGF) drugs, thermal laser treatment and photodynamic therapy (PDT), to prevent the growth of the blood vessels.

The market is experiencing growth on account of the rising prevalence of age-related macular degeneration (ARMD), ocular histoplasmosis, pathologic myopia, angioid streaks, choroidal tears and inflammatory diseases of the choroid and retina. Moreover, the increasing geriatric population, which is more vulnerable to serious health conditions, is acting as another key factor bolstering the market growth. Furthermore, the growing adoption of combination drugs, along with the introduction of long-lasting anti-VEGF drugs, is propelling the demand for CNV treatments worldwide. Other factors, such as improving healthcare infrastructure and the increasing investments in research and development (R&D) activities, are also contributing to the growth of the market.

Key Market Segmentation:

Breakup by Product Type:

Intravenous
Intravitreal

Breakup by Type of Diagnosis:

Fluorescein Angiography (FA)
Indocyanine Green (ICG) Angiography
Spectral Domain Optical Coherence Tomography (OCT)
Others

Breakup by Treatment Type:

Angiogenesis Inhibitors Injection
Photodynamic Therapy
Laser photocoagulation
Low-dose Radiation Therapy
Surgery

Breakup by Application:

Extreme Myopia
Malignant Myopic Degeneration
Age-Related Developments

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Bausch Health Companies Inc., Bayer AG, Gilead Sciences, Inc., F. Hoffmann-La Roche AG, MaaT Pharma, Novartis AG, Pfizer Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Regeneron Pharmaceuticals Inc. and Sanwa Kagaku Kenkyusho Co. Ltd. (Suzuken Co. Ltd.).

Key Questions Answered in This Report:

How has the global choroidal neovascularization market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global choroidal neovascularization market?
What are the key regional markets?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the type of diagnosis?
What is the breakup of the market based on the treatment type?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global choroidal neovascularization market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Choroidal Neovascularization Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product Type

6.1 Intravenous
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Intravitreal
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Type of Diagnosis

7.1 Fluorescein Angiography (FA)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Indocyanine Green (ICG) Angiography
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Spectral Domain Optical Coherence Tomography (OCT)
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Treatment Type

8.1 Angiogenesis Inhibitors Injection
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Photodynamic Therapy
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Laser Photocoagulation
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Low-dose Radiation Therapy
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
8.5 Surgery
- 8.5.1 Market Trends
- 8.5.2 Market Forecast

9 Market Breakup by Application

9.1 Extreme Myopia
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Malignant Myopic Degeneration
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Age-Related Developments
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Bausch Health Companies Inc.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 Bayer AG
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 Gilead Sciences, Inc.
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 F. Hoffmann-La Roche AG
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 SWOT Analysis
- 15.3.5 MaaT Pharma
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
- 15.3.6 Novartis AG
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 Pfizer Inc.
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 Quark Pharmaceuticals Inc. (SBI ALApharma Co., Limited)
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
- 15.3.9 Regeneron Pharmaceuticals Inc.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Sanwa Kagaku Kenkyusho Co. Ltd. (SUZUKEN CO., LTD.)
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트 등의 Copy&Paste도 불가능합니다.

US $ 2,999

￦ 4,196,000

PDF & Excel (5 User License)

PDF & Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy&Paste가 불가능합니다. 인쇄는 5부까지 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 3,999

￦ 5,596,000

PDF & Excel (Corporate License)

US $ 4,999

￦ 6,995,000

※ 부가세 별도

맥락막 신생혈관 시장 보고서 : 제품 유형, 진단 종류, 치료 종류, 용도, 지역별(2025-2033년)

Choroidal Neovascularization Market Report by Product Type, Diagnosis (Fluorescein Angiography, Indocyanine Green Angiography, Spectral Domain Optical Coherence Tomography, and Others), Treatment Type, Application, and Region 2025-2033

본 보고서에서 다루는 주요 질문

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 소개

제5장 세계의 맥락막 신생혈관 시장

제6장 시장 내역 : 제품 유형별

제7장 시장 내역 : 진단 종류별

제8장 시장 내역 : 치료 종류별

제9장 시장 내역 : 용도별

제10장 시장 내역 : 지역별

제11장 SWOT 분석

제12장 밸류체인 분석

제13장 Porter's Five Forces 분석

제14장 가격 분석

제15장 경쟁 구도